A Study of Bevacizumab in Combination With First- or Second-Line Therapy in Subjects With Treated Brain Metastases Due to Non-Squamous NSCLC (PASSPORT)

NCT00312728 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

115

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer
Brain Neoplasms

Interventions

DRUG: bevacizumab
DRUG: First-Line Chemotherapy Agents
DRUG: Second-Line Chemotherapy Agents

Sponsor

Genentech, Inc.